Li, Changzhi
Zhou, Hongjuan
Guo, Lingling
Xie, Dehuan
He, Huiping
Zhang, Hong
Liu, Yixiu
Peng, Lixia
Zheng, Lisheng
Lu, Wenhua
Mei, Yan
Liu, Zhijie
Huang, Jie
Wang, Mingdian
Shu, Ditian
Ding, Liuyan
Lang, Yanhong
Luo, Feifei
Wang, Jing
Huang, Bijun
Huang, Peng
Gao, Song
Chen, Jindong
Qian, Chao-Nan
Funding for this research was provided by:
National Natural Science Foundation of China (81872384, 81672872, 82073220, 81972785, 81773162, 81572901)
Article History
Received: 24 February 2022
Accepted: 24 June 2022
First Online: 14 July 2022
Declarations
:
: Not applicable.
: Not applicable.
: Patent entitled “Anti-novel coronavirus drug based on the binding target of ACE2 and S protein and its application” (China Patent Application No. 2021101658526) is pending for tannic acid. Patent entitled “An anti-SARS-CoV-2 drug” (China Patent Application No. 2021105827561 and PCT/CN2021/097391) is pending for TS-984. The inventors include C.Z.L., C.N.Q., J.D.C., H.J.Z. and Y.X.L. All the other authors declare that they have no competing interests.